Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trialsYoo C, Saborowski A, Hyung J, Wenzel P, Kim I, Wege H, Kim K, Folprecht G, Ryoo B, Schütt P, Cheon J, Götze T, Ryu H, Lee J, Vogel A
|
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinomaMacias RIR, Roessler S, Verstegen MMA
|
Mutational Analysis of Bile Cell-Free DNA in Primary Sclerosing Cholangitis: A Pilot StudyArechederra M, Bik E, Rojo C, Elurbide J, Elizalde M, Kruk B, Krasnodębski M, Pertkiewicz J, Kozieł S, Grąt M, Raszeja-Wyszomirska J, Rullan M, Alkorta-Aranburu G, Oyón D, Fernández-Barrena M, Candels L, Białek A, Krupa Ł, Schneider K, Urman J, Strnad P, Trautwein C, Milkiewicz P, Krawczyk M, Ávila M, Berasain C
|
Understanding Cholangiocarcinoma—perspectives from three European advocacy groupsBaucells E, Morement H, Leonardi P
|
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across EuropeRimassa L, Lamarca A, O'Kane G, Edeline J, McNamara M, Vogel A, Fassan M, Forner A, Kendall T, Adevar J, Casadei-Gardini A, Fornaro L, Hollebecque A, Lowery M, Macarulla T, Malka D, Mariamidze E, Niger M, Ustava A, Bridgewater J, Macias RIR, Braconi C
|